Edgen Stock·Sep 20 2025, 00:39戻る
戻る
Merck's KEYTRUDA Advances Following Favorable EU Regulatory Opinions
Edgen Stock·Sep 20 2025, 00:39
[1] Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer[2] Merck's Keytruda Injectable Version: A Paradigm Shift in Oncology Access and Profitability?[3] Keytruda's FDA Approval of Injectable Form and Its Strategic Implications for Merck's Market Position - AInvest